These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30851117)

  • 1. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases.
    Jung ES; Choi KW; Kim SW; Hübenthal M; Mucha S; Park J; Park Z; Ellinghaus D; Schreiber S; Franke A; Oh WY; Cheon JH
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1727-1735. PubMed ID: 30851117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
    Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
    Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
    Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
    Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
    Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
    Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
    Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
    Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.
    Urcelay E; Mendoza JL; Martinez A; Fernandez L; Taxonera C; Diaz-Rubio M; de la Concha EG
    World J Gastroenterol; 2005 Feb; 11(8):1187-92. PubMed ID: 15754402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.
    Burke KE; Khalili H; Garber JJ; Haritunians T; McGovern DPB; Xavier RJ; Ananthakrishnan AN
    Inflamm Bowel Dis; 2018 Jul; 24(8):1840-1848. PubMed ID: 29718226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.
    Pascual-Oliver A; Casas-Deza D; Cuarán C; García-López S; Corsino-Roche P; Sierra-Moros E; Olier-Martínez P; González-Tarancón R; Vicente-Lidón R
    Inflamm Bowel Dis; 2024 Jun; 30(6):922-929. PubMed ID: 37462462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalizing therapy for inflammatory bowel diseases.
    Ananthakrishnan AN
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):549-58. PubMed ID: 23985004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
    Cardile S; Candusso M; Papadatou B; Bracci F; Knafelz D; Torre G
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):736. PubMed ID: 28441268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.